Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 3 - Revenue (Details Textual)

Note 3 - Revenue (Details Textual) $ / shares in Units, $ in Thousands, € in Millions								1 Months Ended					3 Months Ended				12 Months Ended
	May 19, 2021 USD ($)	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($)	May 02, 2017 USD ($)	Jan. 04, 2017	Jan. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Jan. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Feb. 29, 2020	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Jan. 01, 2019 USD ($)
Contract with Customer, Liability, Current													$ 20,824				$ 20,824		$ 25,116
Contract with Customer, Liability, Noncurrent													18,734				18,734		38,403
Contract with Customer, Liability, Revenue Recognized																	20,400
Number of Technology Licenses						5
Revenues, Total																	25,902		31,418
Increase (Decrease) in Contract with Customer, Liability																	0
Genentech [Member]
Number Of Initial Research Programs	2
Number Of Optional Additional Research Programs	2
Revenue from Contract with Customer, Collaboration Fee On Additional Program	$ 10,000
Revenue from Contract with Customer, Agreement Termination Notice Period Within Material Breach (Day)	90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period Before First Commercial Sale (Day)	90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period After First Commercial Sale (Day)	180 days
Number of Research Programs	4
Number of Performance Obligations	2
Revenue, Remaining Performance Obligation, Amount													12,600				12,600
Revenues, Total																	3,139		1,950
Genentech [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations	5
Genentech [Member] \| Platform Technology License [Member]
Number of Performance Obligations	2
Genentech [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations	1
Seattle Genetics Inc. [Member]
Number of Performance Obligations					3
Revenue, Remaining Performance Obligation, Amount													17,100				17,100
Contract with Customer, Liability, Current													11,600				11,600
Contract with Customer, Liability, Noncurrent													2,900				2,900
Amended Collaboration Agreement, Resale of Stock, Period (Day)				60 days
Revenues, Total																	8,287		768
Seattle Genetics Inc. [Member] \| Private Placement [Member]
Contract with Customer, Liability, Total				$ 3,300
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares				3,706,174
Sale of Stock, Consideration Received on Transaction				$ 13,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares				$ 3.51
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares				$ 2.61
Seattle Genetics Inc. [Member] \| License and Collaboration Agreement [Member]
Number of Research Programs				3	3
Number of Performance Obligations					6
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)					12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)					90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)					180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)					90 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)					90 days
Number Of Licenses					3
Number Of Swap Options					2
Seattle Genetics Inc. [Member] \| Platform Technology License [Member]
Number of Performance Obligations					3
Number of Target Programs					3
Seattle Genetics Inc. [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations					1
Seattle Genetics Inc. [Member] \| Other Arrangement [Member]
Number of Research Programs					2
Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned					$ 4,900
Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member] \| Sales Milestone Payments [Member]
Contract with Customer, Liability, Revenue Recognized														$ 1,500						$ 4,200
Collaborative Arrangement Allocable Arrangement Consideration Allocation															$ 5,000
Seattle Genetics Inc. [Member] \| Antibody Target Swap [Member]
Number of Performance Obligations					2
Seattle Genetics Inc. [Member] \| Collaborative Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax																	5,000
Seattle Genetics Inc. [Member] \| Collaborative Arrangement [Member] \| Subsequent Event [Member]
Revenue from Contract with Customer, Excluding Assessed Tax								$ 5,000
Astra Zeneca A B [Member]
Contract with Customer, Liability, Total													700				700
Research Collaboration Agreement Period (Year)						5 years
Revenue, Remaining Performance Obligation, Amount													7,500				7,500
Contract with Customer, Liability, Current													500				500
Contract with Customer, Liability, Noncurrent													6,900				6,900
Amended Collaboration Agreement, Resale of Stock, Period (Day)			60 days
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation									$ 5,000	$ 4,700
Revenues, Total											$ 13,000						9,117		18,919
Number of Discovery Programs Discontinued										1
Capitalized Contract Cost, Net, Total						$ 1,600							200				200
Capitalized Contract Cost, Gross																							$ 1,100
Capitalized Contract Cost, Amortization																	300		300
Astra Zeneca A B [Member] \| Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares			3,584,230
Sale of Stock, Consideration Received on Transaction			$ 10,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares			$ 2.79
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares			$ 2.60
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations						16
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)						12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)						90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)						180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)						180 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)						180 days
Number of Novel Proteins						4
Agreement Termination Notice Period Upon Of Breach Of Payment Obligations (Day)						30 days
Remaining Performance Obligation, Estimated Term (Month)						12 months
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Minimum [Member]
Number of Collaboration Products						2
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Maximum [Member]
Number of Collaboration Products						4
Number of Programs						2
Number of Research Licenses						4
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						$ 45,000
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Sales Milestone Payments [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						12,500
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Estimated Development And Manufacturing Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						14,200
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Estimated Phase 2a Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						4,700
Astra Zeneca A B [Member] \| Additional Other Research Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						$ 4,700
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Number of Performance Obligations																					10	10
Revenue, Remaining Performance Obligation, Amount													5,000				5,000
Contract with Customer, Liability, Current													900				900
Contract with Customer, Liability, Noncurrent													4,100				4,100
Contract with Customer, Liability, Revenue Recognized													4,900			$ 7,100
Number of Novel Proteins																					1	1
Number of Programs												5									3	3
Revenues, Total																	5,359		4,070
Capitalized Contract Cost, Net, Total													0				0
Capitalized Contract Cost, Amortization																	100		100
Number Of Separate Performance Obligations							2
Number of Combined Performance Obligations							2
Research Term ,Extension Period (Year)												12 years
Number Of Preclinical Stage Programs												2
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total																							$ 500
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations							4
Number of Collaboration Products							2
Number of Programs																					5	5
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member]
Contract with Customer, Liability, Revenue Recognized																	4,300	€ 3.8
Number of Collaboration Products							4
Number Of Separate Performance Obligations							2
Number of Combined Performance Obligations							2
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member] \| Minimum [Member]
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)																					90 days	90 days
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)																					120 days	120 days
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Co-Development Collaboration Product Collaboration [Member]
Number of Collaboration Products												1
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Servier Developed Collaboration Products [Member]
Number of Collaboration Products												1
License [Member] \| Genentech [Member]
Contract with Customer, Liability, Total	$ 20,000
Contract with Customer, Liability, Current													7,800				7,800
Contract with Customer, Liability, Noncurrent													$ 4,800				$ 4,800
License [Member] \| B P Assets X I I Inc [Member]
Revenue, Remaining Performance Obligation, Amount		$ 6,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		4,000
License [Member] \| B P Assets X I I Inc [Member] \| Exclusive Product License Agreement [Member]
Contract with Customer, Liability, Total		10,000
Revenue, Remaining Performance Obligation, Amount		10,000
Revenue from Contract with Customer, Contribution Towards Manufacturing Activities		$ 4,000
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)		9 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)		60 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)		120 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)		180 days
Revenue from Contract with Customer, Agreement Termination Notice Period, Non-Payment Of Undisputed Amounts (Day)		60 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)		180 days
Revenue from Contract with Customer, Agreement Obligation Cost		$ 4,000
Contract with Customer, Liability, Revenue Recognized																			$ 5,700
License [Member] \| Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax					$ 30,000
License [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax																					$ 32,000	€ 30.0
Research And Development Services [Member] \| Genentech [Member]
Research Collaboration Agreement Period (Year)	3 years
Research And Development Services [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Number of Development Milestones																					3	3